Search Results - "Weems, G."

RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial by Camidge, D.R., Gadgeel, S.M., Wilkins, H.J., Weems, G., Santana-Davila, R., Johnson, M.

Get full text

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial by Wang, J., Liu, S.V., Uronis, H.E., Wu, C., Mahalingam, D., Spira, A., Carter, L., Hu, X., Weems, G., Wilkins, H.J., Duska, L.R., Kelly, K.

Get full text

1169PRORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial by Camidge, D R, Gadgeel, S M, Wilkins, H J, Weems, G, Santana-Davila, R, Johnson, M

Get full text

A Novel Immunotherapy: LYC-55716, a Small-molecule RORγ Agonist, in Clinical Trials for Head and Neck Squamous Cell Carcinoma by Hu, X., Liu, X., Li, H., Bogdan, M., Gao, Y., Fox, B., Weems, G., Wilkins, H.J., Carter, L.

Get full text

Novel immunooncology agent, small-molecule rorγ agonist lyc-55716: Tumor selection process for phase IIa expansion and rationale for clinical evaluation in ovarian cancer following phase I dose finding by Hu, X., Liu, X., Li, H., Bogdan, M., Gao, Y., Fox, B., Weems, G., Wilkins, H.J., Carter, L.

Get full text

1139PDNovel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial by Wang, J, Liu, S V, Uronis, H E, Wu, C, Mahalingam, D, Spira, A, Carter, L, Hu, X, Weems, G, Wilkins, H J, Duska, L R, Kelly, K

Get full text

Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC by Patel, J. D., Azzoli, C. G., Weems, G. A., Koutsoukos, A., Zatloukal, P., Kelly, K.

“…Abstract only…”
Get full text

Results of a randomized phase II study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment by Berger, E. R., Ciuleanu, T., Hart, L., Chi, K. N., Alexandre, J., Oudard, S., Kahatt, C., Weems, G., Cvitkovic, E., MacDonald, J. R.

“…Abstract only 5068 Background: Currently, no available treatments demonstrate an increase in survival for patients (pts) with hormone- refractory prostate…”
Get full text

Irofulven (IROF) combined with oxaliplatin (OXA) in advanced hepatocellular carcinoma (HCC) patients (pts): Phase I study (preliminary results) by Goldwasser, F., Houédé, N., Bertheault-Cvitkovic, F., Misset, J., Raymond, E., Benettaib, B., Kahatt, C., MacDonald, J. R., Weems, G.

“…Abstract only 14082 Background: IROF, a semisynthetic derivative of the natural product illudin S, is a novel DNA binding agent that has demonstrated antitumor…”
Get full text

Activity of irofulven (IROF) combined with capecitabine (CAPE) in patients (pts) with advanced thyroid carcinoma: Phase II international multicenter study (preliminary results) by Droz, J., Baudin, E., Medvedev, V., Delord, J., Kane, M., Kloos, R., Ringel, M., Kahatt, C., Weems, G., Shah, M.

“…Abstract only 15511 Background: IROF, the first compound of the acylfulvene class to enter clinical trials, has demonstrated antitumor activity in a variety of…”
Get full text

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer by Seiden, Michael V., Gordon, Alan N., Bodurka, Diane C., Matulonis, Ursula A., Penson, Richard T., Reed, Eddie, Alberts, Dave S., Weems, Garry, Cullen, Michael, McGuire, William P.

“…To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive…”
Get full text

Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results by Falcon-Lizaraso, S., Leon Chong, J., Perazzo, F., Goldwasser, F., Cohn, A., Kahatt, C., Weems, G., Eckhardt, S. G.

“…Abstract only…”
Get full text

Clinical activity of irofulven in hormone refractory prostate cancer by Cvitkovic, E., Kahatt, C., Senzer, N., Tombal, B., Culine, S., Raymond, E., Alexandre, J., Weems, G., MacDonald, J.

“…Abstract only…”
Get full text

Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results by Falcon-Lizaraso, S., Leon Chong, J., Perazzo, F., Goldwasser, F., Cohn, A., Kahatt, C., Weems, G., Eckhardt, S. G.

“…Abstract only…”
Get full text

Clinical activity of irofulven in hormone refractory prostate cancer by Cvitkovic, E., Kahatt, C., Senzer, N., Tombal, B., Culine, S., Raymond, E., Alexandre, J., Weems, G., MacDonald, J.

“…Abstract only…”
Get full text

Phase I trial of irofulven (MGI 114) plus docetaxel in advanced cancers by Ahmann, F. R., Culine, S., Wilding, G., Papadopoulos, K., Raftopoulos, H., Duvillie, L., Weems, G., Puzon, C., Shah, A., Terret, C.

“…Abstract only…”
Get full text

The Impact of Midpoint Responses and Reverse Coding on Survey Data by Weems, Gail H., Onwuegbuzie, Anthony J.

“…Counselors conducting survey research have many item format options to contemplate. This study examined midpoint selection and the effect on reliability of (a)…”
Get full text

LIGHT PARAFFINS Their Commercial Isomerization by EVERING, B. L.

Get full text

Centennial of the United States Patent Laws by Weems, David G.

Get full text

Letter 1 -- No Title by Weems, David G

Get full text